Stocks of Clover Health Investments Corp (NASDAQ:CLOV) traded higher last session on Wall Street, down -4.70% to $0.89.
CLOV stock price is now 18.15% away from the 50-day moving average and -8.90% away from the 200-day moving average. The market capitalization of the company currently stands at $441.83M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $7 to $3, Cowen Upgraded its rating from Underperform to Market Perform for Clover Health Investments Corp (NASDAQ: CLOV). On February 02, 2022, Canaccord Genuity recently initiated its ‘Buy’ rating on the stock quoting a target price of $6, while ‘SVB Leerink’ rates the stock as ‘Mkt Perform’
In other news, Loengard Anna U, Director bought 137,000 shares of the company’s stock on Mar 14 ’24. The stock was bought for $100,010 at an average price of $0.73. Upon completion of the transaction, the Director now directly owns 538,841 shares in the company, valued at $0.48 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 14 ’24, Director Loengard Anna U bought 13,625 shares of the business’s stock. A total of $9,946 was incurred on buying the stock at an average price of $0.73. This leaves the insider owning 15,125 shares of the company worth $13461.25. A total of 25.30% of the company’s stock is owned by insiders.
During the past 12 months, Clover Health Investments Corp has had a low of $0.61 and a high of $1.63.
The net profit margin was -8.66% and return on equity was -53.26% for CLOV. The company reported revenue of $346.92 million for the quarter, compared to $321.99 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.74 percent.
